Skip to main content

Table 2 CRT changes following AFL PRN treatment

From: Clinical outcomes of switching to aflibercept using a pro re nata treatment regimen in patients with neovascular age-related macular degeneration who incompletely responded to ranibizumab

CRT reduced N (%) CRT increased N (%)
≥50μm 23 (12%) ≥50μm 38 (21%)
≥100μm 8 (4%) ≥100μm 16 (9%)